Allergy Therapeutics (LON:AGY) Share Price Crosses Below 200 Day Moving Average – Here’s Why

Shares of Allergy Therapeutics plc (LON:AGY) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 10.60 and traded as low as GBX 7.67. Allergy Therapeutics shares last traded at GBX 8, with a volume of 47,689 shares.

Allergy Therapeutics Price Performance

The company has a market cap of £506.60 million, a PE ratio of -8.25, a P/E/G ratio of -30.70 and a beta of 0.89. The business has a 50-day simple moving average of GBX 9.90 and a 200-day simple moving average of GBX 10.60. The company has a quick ratio of 1.48, a current ratio of 1.13 and a debt-to-equity ratio of 629.58.

Allergy Therapeutics (LON:AGY) last issued its quarterly earnings results on Tuesday, March 31st. The company reported GBX (0.38) earnings per share (EPS) for the quarter. The business had revenue of GBX 3,628 million for the quarter. Allergy Therapeutics had a positive return on equity of 409.00% and a negative net margin of 85.46%. Equities research analysts anticipate that Allergy Therapeutics plc will post -2.56 EPS for the current year.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.